Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Parkinson Disease

• A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease
• High-Dose Ambroxol in GBA1-Related Parkinson
• Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients
• A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease
• Montelukast in Parkinson Disease
• PET Imaging Evaluation of [11C]SY08
• Effectiveness of Botulinum Toxin in Freezing of Gate in Parkinson's Disease Walking in Parkinson's Disease.
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
• A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
• Personalized Real-Time DBS and PD Mechanisms
• Early Parkinson's Disease Monotherapy With CVN424
• A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD)
• Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
• Effect of Folic Acid in Levodopa Treated Parkinson's Disease Patients
• Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease
• A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
• Single Ascending Doses of HER-096 in Healthy Subjects
• Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease
• Study to Evaluate the Safety and Efficacy of ESC-derived Dopamine Progenitor Cell Therapy in PD Patients
• Istradefylline Effect Protocol on Parkinson's Disease Tremor
• Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients
• [18F]MC225-PET in Neurodegenerative Disease
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers
• The Dutch Parkinson GBA Ambroxol Trial (DUPARG-AMBROXOL)
• Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
• Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002)
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
• Pimavanserin for Sleep in Parkinson Disease
• Single and Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of NM-101
• Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease
• Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Ketones
• Ambroxol to Slow Progression in Parkinson Disease
• Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
• Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's Disease
• Role of Saffron and Chamomile in the Management of Parkinson's Disease
• Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease
• A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants With Parkinson's Disease
• Methylphenidate for Apathy in Veterans With Parkinson's Disease
• A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
• Altropane Dose for Imaging Patients With Suspected Parkinson's Disease
• Relative Bioavailability and Food Effect Study of CVN424
• Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease
• Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
• Pyridostigmine for the Treatment of Constipation in Parkinson Disease
• Comparing Antipsychotic Medications in LBD Over Time
• Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants
• Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease
• Choice of Anaesthesia in Microelectrode Recording-Guided Deep-Brain Stimulation for Parkinson's Disease(CHAMPION)
• An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of UCB0599 in Study Participants With Parkinson's Disease
• AMDX-2011P Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
• A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
• Intranasal Human FGF-1 for Subjects With Parkinson's Disease
• Effect of Doxycycline in Levodopa Treated Parkinson's Disease Patients
• Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
• Sustained Release Oral Formulation for Treatment of Parkinson's Disease
• Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
• A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease
• A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
• A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Diseas
• EC50 of Dexmedetomidine in Deep Brain Stimulation Implantation of Patients With Parkinson's Disease
• A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
• Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
• Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease
• A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
• A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
• Istradefylline for Parkinson Disease With Cognitive Impairment
• A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
• A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea
• Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia
• Ambroxol as a Disease-modifying Treatment in GBA-PD
• Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
• Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
• A Clinical Study Evaluating Efficacy of Pirepemat on Falls Frequency in Patients With Parkinson's Disease (PD)
• Mass Balance Recovery and Metabolite Identification of Carbon-14 BIA 28-6156
• Multiple N-of-1 Trials of (Intermittent) Hypoxia Therapy in Parkinson's Disease
• Dexmedetomidine Prevents Postoperative Delirium After Deep Brain Stimulation in Patients With Parkinson's Disease
• Comparative Bioavailability Study of Carbidopa/Levodopa Extended-Release Tablets Under Fasting and Fed Conditions
• Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
• Terazosin and Parkinson's Disease Extension Study
• Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA
• Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease
• A 6-month Study to Evaluate Sulforaphane Effects in PD Patients
• NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa
• Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study
• A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
• A Study of CST-2032 in Subjects With Cognitive Impairment
• Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease
• Chinese Herbal Medicine Treatment Based on Subgroup Differentiation as Adjunct Therapy for Parkinson's Disease: a Pilot add-on, Randomised, Controlled, Pragmatic Clinical Trial
• eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
• OpicApone Sleep dISorder
• OpiCapone Effect on Motor Fluctuations and pAiN
• Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)
• High Fiber in Parkinson's Disease
• Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients
• Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease
• Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease
• Ketamine for the Treatment of Depression in Parkinson's Disease
• A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)
• Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
• PPMI Tau PET Imaging
• Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease
• Apomorphine Effects on Pain in Parkinson's Disease
• A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
• Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease
• Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease
• A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease
• A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
• Study to Investigate the Effect of Hypoestes Rosea Powder in Parkinson's Disease
• Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
• ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies
• A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD
• Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug
• A Study to Assess the Safety and Tolerability of Surgical Implant of MSK-DA01 Cells for Advanced Parkinson's Disease
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
• Quantitative Imaging of Brain Glymphatic Function in Humans
• 12 Weeks Vitamin D Supplementation and Physical Activity in PD Patients With DBS
• A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
• Open-label Trial in Parkinson's Disease (PD)
• Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
• A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders
• Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease
• 18F-DOPA II - PET Imaging Optimization
• Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets
• Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease
• The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson's Disease Patients
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
• A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
• A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)
• Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease
• A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD
• A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients
• A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003
• Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult Subjects
• Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
• to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers
• PK Study of WD-1603 in Healthy Subjects
• Improving Quality of Life in Early Parkinson's Disease
• OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
• A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
• Treatment of Chronic Constipation in Parkinson's Disease
• A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions
• Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations
• Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
• WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects
• Lundbeck TOMs Orthostatic Hypotension
• Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD
• Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease
• Tocotrienols in Parkinson's Disease (PD)
• Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety "Roll-over" Study (Rollover)
• A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)
• Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder
• FDOPA PET and Nutritional Support in Parkinson's Disease
• Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease
• Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease
• A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
• Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])
• Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
• Terazosin Effect on Cardiac Changes in Early Parkinson's Disease
• A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers
• Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
• Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
• Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components
• Pimavanserin vs. Quetiapine for the Treatment Parkinson's Psychosis
• Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment
• A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients
• The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease
• A Through QT/QTc Study of KW-6356
• PK Study in Patients With Parkinson's Disease With IZD174
• A Study of TAK-071 in People With Parkinson Disease
• Dopaminergic restauratIon by intraVEntriculaire Administration
• Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects
• Exenatide Treatment in Parkinson's Disease
• A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease
• Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
• Lu AF28996 in Participants With Parkinson's Disease (PD)
• Melatonin on Clock Genes in Parkinson's Disease
• Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease
• Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets
• Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.
• SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease
• [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor
• Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)
• Is Long-term Use of Amantadine Effective in PD?
• Intranasal Insulin in Parkinson's Disease
• Social Decision Making in Parkinson's Disease
• [18F]F-DOPA Imaging in Patients With Autonomic Failure
• Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease
• CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)
• Flexible-Dose Trial in Early Parkinson's Disease (PD)
• A Study to Determine the Dose of WIN-1001X by Evaluating Efficacy and Safety in Early Parkinson's Disease Patients
• Cardiac Changes in Early Parkinson's Disease: A Follow up Study
• Fixed-Dose Trial in Early Parkinson's Disease (PD)
• A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
• Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
• An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.
• Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study
• Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)
• Trial of Ondansetron as a Parkinson's HAllucinations Treatment
• Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
• Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
• A Clinical Study Trial of Phenlarmide in China
• A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China
• Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease
• A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
• A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease
• NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
• AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
• A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease
• Phase 1/2a Clinical Trial of PR001 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
• Monitoring Anti-Dementia Drugs by Serum Levels
• Tolerance to NeuroEPO in Parkinson Disease
• Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease
• A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin
• Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT
• Study to Evaluate DNL151 in Subjects With Parkinson's Disease
• A Trial of tPCS on Parkinson's Disease OFF State
• A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease
• A Study of LY03003 in Patients With Early-stage Parkinson's Disease
• Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients
• Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects
• Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
• A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).
• Safinamide for Levodopa-induced Dyskinesia (PD-LID)
• the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease
• Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PD
• Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
• A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
• Serotonin in Impulse Control Disorders in Parkinson's Disease
• Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease
• Modulation of Gut Microbiota by Rifaximin in PD Patients
• A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia
• Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.
• Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19
• A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia
• Trial of Parkinson's And Zoledronic Acid
• A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
• Terazosin for Parkinson's Disease
• Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers
• Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease
• Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
• A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
• Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in PD Patients With Motor Fluctuations
• Pilot Trial of Transnasal Nicotine in Parkinson Disease
• Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine
• A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
• Overnight Switch From Rasagiline To Safinamide
• Effect of Safinamide on Parkinson's Disease Related Chronic Pain
• Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease
• Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The "UP" Study
• A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects
• Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
• A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects
• Staccato Apomorphine Single and Multi Dose PK
• Relative Bioavailability and Bioequivalence of Opicapone
• 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease
• A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells
• Biomarker Assessments of Leukine During Treatment of Parkinson's Disease
• Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)
• A Study to Evaluate the Safety and Tolerability of ABBV-951 in Participants With Parkinson's Disease (PD)
• Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study
• Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease
• ANAVEX2-73 Study in Parkinson's Disease Dementia
• Nabilone for Non-motor Symptoms in Parkinson's Disease
• Nabilone for Non-motor Symptoms in Parkinson's Disease
• A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
• Idebenone Treatment of Early Parkinson's Diseasesymptoms
• Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease
• A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
• Study to Evaluate DNL201 in Subjects With Parkinson's Disease
• A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
• The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)
• Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals
• Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
• Study of the Fecal Microbiome in Patients With Parkinson's Disease
• A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Patients With Motor Fluctuations
• Dopamine Effect on Inhibitory Control
• PF 06412562 in Subjects With Advanced Stage Parkinson's Disease
• SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis
• PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
• Antidepressants Trial in Parkinson's Disease
• Atomoxetine for Freezing of Gait in Parkinson's Disease
• Clinical Laboratory Evaluation of Chronic Autonomic Failure
• Cannabis Oil for Pain in Parkinson's Disease
• Virtual Reality for Parkinson's Disease
• Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
• Use of Low-dose Zolpidem in Parkinson's Disease
• Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease
• BTRX-246040 Study in Subjects With Parkinson's Disease With Motor Fluctuations
• Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil
• Effects of Lingzhi on Disease Progression in Patients With Untreated Early Parkinson's Disease
• Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease
• Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss
• A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
• Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients
• Microbiota Intervention to Change the Response of Parkinson's Disease
• A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease
• Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH)
• 11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes
• Study of Clonidine Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease:
• A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
• The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
• Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain
• A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.
• Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
• Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm
• TSPO-PET for Neuroinflammation in Parkinson's Disease
• Effects of Exenatide on Motor Function and the Brain
• Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism
• Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm
• Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
• A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease
• Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease
• To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
• Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease
• A Study to Investigate a New Treatment in Patients With Parkinson's Disease
• A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuati
• Trial of Probiotics for Constipation in Parkinson's Disease
• A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
• Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
• Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)
• A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
• Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease
• DNS-7801 vs. Placebo in Parkinson's Disease
• A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
• Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease
• Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
• A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
• Single Ascending Dose Study of MEDI1341 in Healthy Volunteers
• Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease
• Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
• Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease
• Identification of a Biomarker Predictive of Evolution of Parkinson Disease
• Brain Perfusion & Oxygenation in Parkinson's Disease With NOH
• Measuring Parkinson's Disease Progression
• Nilotinib in Parkinson's Disease
• Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease
• Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease
• BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness
• Safety and Efficacy of DA-9805 for Parkinson's Disease
• A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
• Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
• Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease
• Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients
• Dopaminergic Modulation of Declarative Memory
• Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
• Pharmacokinetic of Levodopa Study in Healthy Males
• Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067
• Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone
• Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
• Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease
• Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?
• Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
• Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD)
• Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease
• Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
• Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.
• Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation
• 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
• A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
• Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients
• Phase I, KM-819 in Healthy Subjects for Parkinson's Disease
• Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease
• Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease
• A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
• A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
• Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease
• Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease
• A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
• The Stanford Parkinson's Disease Plasma Study
• Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment
• Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
• Safety and Efficacy of Liraglutide in Parkinson's Disease
• Ambroxol in Disease Modification in Parkinson Disease
• Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease
• A Study of KW-6356 in Subjects With Early Parkinson's Disease
• Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study
• Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3
• The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease
• Ambroxol as a Treatment for Parkinson's Disease Dementia
• Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
• A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation
• Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
• Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes
• TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease
• Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
• Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)
• A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients
• Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
• Efficacy and Safety of Opicapone in Clinical Practice
• RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease
• Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients
• A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
• A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets
• Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease
• A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)
• Buspirone in Parkinson's Disease
• A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
• Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease
• Image Parkinson's Disease Progression Study
• Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's Disease
• Non Motors Aspects in De Novo Parkinson's Disease
• Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers
• A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
• Parkinsonian Brain Repair Using Human Stem Cells
• Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
• Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms
• Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa
• Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202
• Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites
• Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON
• Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease
• A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease
• Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)
• Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)
• Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)
• Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202
• Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202
• Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients
• Expanded Access of Pimavanserin for Patients With PD Psychosis
• Levodopa Benserazide Generic Formulation Versus the Originator
• A Pilot Study of Suvorexant for Insomnia in Parkinson Disease
• Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease
• Study of Parkinson's Early Stage With Deferiprone
• A Clinical Study in Advanced Parkinson's Disease Investigating the Long Term Safety of ND0612 Administered as a Continuous SC Infusion
• Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease
• Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
• TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
• Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
• Apomorphine in Parkinson's Disease Patients With Visual Hallucinations
• Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
• Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
• Mucuna Pruriens Therapy in Parkinson's Disease
• Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy
• Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease
• An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients
• Study of Urate Elevation in Parkinson's Disease, Phase 3
• Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease
• A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects
• Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease
• Effect of SQJZ Herbal Mixtures on Non-motor Symptoms of Parkinson's Disease
• A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004
• Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
• A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients
• A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects
• Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease
• Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients
• Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia
• A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214
• Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia
• A Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of ND0612H, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease
• Systemic Synuclein Sampling Study (S4)
• PF-06669571 In Subjects With Idiopathic Parkinson's Disease
• A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
• Pharmacokinetic Study in Healthy Volunteers
• Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®
• A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
• Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease
• Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients
• Mirabegron in Parkinson Disease and Impaired Cognition
• Domperidone and Risk of Sudden Cardiac Death
• A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
• INfusion VErsus STimulation in Parkinson's Disease
• Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease
• The Use of Botox in Advanced Parkinson's Patients Experiencing Pain
• Treating Bacterial Overgrowth in Parkinson's Disease
• Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
• Safety and Biomarker Study of EPI-589 in Parkinson's Disease
• Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
• Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients
• Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease
• Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)
• A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients
• Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia
• A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients
• Study of IRX4204 for Treatment of Early Parkinson's Disease
• Kinematic-guided BoNT-A Treatment for ET and PD Tremor
• Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
• Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach
• The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia
• Clinical Registry of Patients Under Treatment With Atypical Antipsychotics
• An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease
• Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999
• Cough According to Stimulus Type in PD
• Fesoterodine on Urgency Episodes in Parkinson's Disease Population
• Azilect® In Wearing-Off (AIWO)
• Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
• Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment
• Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine
• Melatonin for Nocturia in Parkinson's Disease
• Randomized Safety Study of CVT-301 Compared to an Observational Control Group
• L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease
• Infusion of Apomorphine: Long-term Safety Study
• A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants
• A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
• A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants
• A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
• CNS Uptake of Intranasal Glutathione
• Pharmacokinetic Study in Healthy Males
• Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone
• Effect of Opicapone at Steady State on Warfarin Pharmacokinetics
• Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers
• Nilotinib in Cognitively Impaired Parkinson Disease Patients 001
• Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.
• Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
• A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease
• SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
• Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators
• Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
• Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease
• Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease
• Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease
• Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
• Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
• Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole
• Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
• Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease
• Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease
• The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease
• Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease
• Treatment of Apomorphine-induced Skin Reactions: a Pilot Study
• A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease
• A Study to Examine APL-130277 in Patients With Parkinson's Disease
• Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
• Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease
• Ambulosono Rasagiline Musical Walking Study
• Effects of Cholinergic Augmentation on Measures of Balance and Gait
• Open-Label Safety Study of ADS-5102 in PD Patients With LID
• Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease
• Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients
• The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
• Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease
• The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
• Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide
• Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
• Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
• Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
• Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
• An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
• Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics
• Efficacy of Isradipine in Early Parkinson Disease
• Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease
• Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease
• Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
• Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
• Validation of DaTscan for Detection of Parkinson Disease Related Disorders
• ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
• Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's Disease
• Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) "After Multiple Oral Doses" in Healthy Volunteers
• Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease
• Helicobacter Pylori Eradication Study in Parkinson's Disease
• Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
• Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease
• Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment
• MIRT and Rotigotine in the Early Stage of PD
• A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
• Single Ascending Dose Study of PRX002 in Healthy Subjects
• A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
• Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects
• Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
• An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
• Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules
• Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067
• Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease
• Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.
• Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism
• Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
• Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain
• Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET
• Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury
• Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
• Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
• Erythromycin in Parkinson's Disease
• Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment
• Trial of Exenatide for Parkinson's Disease
• Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
• A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
• Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects
• A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications
• A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation
• A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
• Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
• Motor Response to Sildenafil in PD
• A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
• A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
• A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease
• Early Versus Late Introduction of STN DBS in PD Patients With Motor Complications
• A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612
• Leukine (Sargramostim) for Parkinson's Disease
• A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline
• Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease
• Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease
• Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease
• Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial
• Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease
• A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.
• The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography
• A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease
• Anesthesia for Deep Brain Stimulation
• Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
• Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy
• Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
• Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
• Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
• Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations
• Study of Zonisamide in Early Parkinson Disease
• Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study
• Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism
• Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
• A Pilot Study of Oxaloacetate in Subjects With Treated PD
• Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)
• Caffeine as a Therapy for Parkinson's Disease
• Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations
• A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease
• A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients
• A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease
• Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
• Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
• A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease
• Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease
• Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers
• A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE
• Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease
• Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease
• Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth
• Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
• Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease
• Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women
• Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
• Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
• A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy Men
• Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations
• A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
• A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
• A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients
• A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients
• A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients
• A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients
• Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
• A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
• A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
• Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients
• A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067
• Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)
• Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
• Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease
• Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
• Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression
• A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders
• Cardiovascular Events in Parkinson's Disease Patients
• A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease
• Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease
• Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528
• Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide
• Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction
• Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide
• Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa
• Effect of Rasagiline on BIA 9-1067 Pharmacokinetics
• Effect of BIA 9-1067 on Rasagiline Pharmacokinetics
• Effect of BIA 9-1067 on Cardiac Repolarization in Healthy Adult Men and Women
• PharmacoMRI of Parkinson Disease
• PET Study in Parkinson's Disease Patients
• Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease
• Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
• The Effect of Donepezil on Gait and Balance in Parkinson's Disease
• Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects
• A Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male Subjects
• PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy
• Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic
• Mild Cognitive Impairment in Parkinson's Disease
• An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
• Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites
• Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)
• Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations
• Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease
• A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
• Single Dose Study to Assess the Pharmacokinetics of SCH 900800 in Subjects With Parkinson's Disease Being Treated With Levodopa (L-DOPA) (P08235)
• A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy
• A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease
• Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
• Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
• A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
• Treatments for Insomnia in Patients With Parkinson's Disease
• Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
• A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease
• A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease
• Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China
• Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease
• Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
• The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
• N-Acetylcysteine for Neuroprotection in Parkinson's Disease
• Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects
• Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls
• Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a
• To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers
• Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease
• A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain
• The Effects of Sertraline on Depression in Parkinson's Disease
• Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects
• Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease
• Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
• Treatment of Depression in Parkinson's Disease
• Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study
• High and Low Dose Carbidopa Treatment of Parkinson's Disease
• Intranasal Glutathione in Parkinson's Disease
• Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
• Emotion, Mood and Executive Function in Parkinson's Disease (PD)
• Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
• The Effect of Rasagiline on Cognition in Parkinson's Disease
• A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda
• A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease
• a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients
• Use of Zolpidem in Parkinson's Disease
• Bee Venom for the Treatment of Parkinson Disease
• Varenicline for Gait and Balance Impairment in Parkinson Disease
• Cognitive Decline in Non-demented PD
• Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations
• ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
• Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease
• Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support
• Safety, Tolerability, and Efficacy of Donepezil (Aricept) in Parkinson' s Disease (PD) Patients With Dementia
• A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)
• Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease
• The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy
• Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms
• Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens
• A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
• Clinical and Economic Impact of Duodopa: Long-term Effectiveness Study in Advanced Parkinson's Disease Patients
• 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
• Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off
• 18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging
• Pioglitazone in Early Parkinson's Disease
• Study On Utilization Of Cabergoline For Compliance With Risk Minimization Activities (SUCRE)
• Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea
• A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging
• Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
• The Effect of Methylphenidate on Non-motor Symptoms and Postural Control in Parkinson's Disease.
• A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients
• Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease
• Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
• Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
• Nicotine Treatment of Impulsivity in Parkinson's Disease
• An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
• A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease
• Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
• Caffeine for Motor Manifestations of Parkinson's Disease
• Pilot Study of Maintenance Therapy With Intravenous AMANTADINE
• Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease
• Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease
• Glutathione (GSH) In The Treatment of Parkinson's Disease
• A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease
• Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
• Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
• A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias
• A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects
• Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
• A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)
• A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
• A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa
• A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease
• Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression
• A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa
• A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
• Effects of Vitamin D in Parkinson's Disease (PD)
• Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
• Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease
• Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611
• Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
• An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
• Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia
• Validation of Dyskinesia Rating Scales
• Levodopa Concentration Profile With Stalevo 75/125 mg
• Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
• Extended Long-Term Safety Study of KW-6500
• Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)
• Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500
• Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
• Naltrexone for Impulse Control Disorders in Parkinson's Disease
• Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
• Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease
• Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study
• Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease
• Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
• Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease
• MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
• Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
• A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
• Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients
• Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
• Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease
• Safety Study of Erythropoietin (EPO) in Parkinson's Disease
• Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists
• A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients
• Natural History of Levodopa-Induced Dyskinesia (LID)
• The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems
• Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
• Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily
• A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
• Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
• Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
• Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy
• Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
• Azilect + Antidepressant Chart Review
• Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
• Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease
• A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
• Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study
• Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease
• Dopaminergic Loss and Pain in Parkinson's Disease
• ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
• Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease
• An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease
• An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
• Duodenal Levodopa Infusion, Quality of Life and Autonomic Nervous System in Parkinson's Disease
• Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II)
• Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease
• Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)
• Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
• Amitiza in Constipation Associated With PD (Parkinson's Disease)
• Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon
• Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors
• A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.
• Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline
• Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease
• Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics
• Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
• A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease
• Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients
• Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease
• A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
• A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa
• A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
• Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients
• Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
• Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies
• Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
• Safety of Urate Elevation in Parkinson's Disease
• Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease
• Botulinum A Toxin in Patients With Parkinson's Disease
• Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease
• Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease
• Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease
• Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients
• Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia
• Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients
• Fipamezole in Neurogenic Orthostatic Hypotension
• Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease
• Rasagiline and Apathy in Parkinson's Disease
• Parkinson's Disease Isradipine Safety Study
• High and Low Dose Carbidopa Treatment of Parkinson's Disease
• Effects of Coenzyme Q10 (CoQ) in Parkinson Disease
• SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)
• SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease
• The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease
• A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions
• A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions
• Lubiprostone as a Treatment for Constipation in Parkinson's Disease
• Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease
• Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
• Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD
• Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
• A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
• Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease
• Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
• Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164
• Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease
• Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
• Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients
• Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)
• Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
• Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)
• Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease
• Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease
• Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)
• An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
• Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)
• Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease
• Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
• Compassionate Use Study of Pergolide in Patients With Parkinson's Disease
• Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease
• The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease
• Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
• Intravenous Versus Inhalational Anesthesia in Parkinson's Disease
• Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects
• Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy
• Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation
• MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
• Study to Evaluate SYN115 in Parkinson's Disease
• Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
• Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
• Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine
• An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
• A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery
• An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease
• An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.
• Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
• Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study
• Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease
• Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease
• Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa
• Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD
• Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT
• PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding
• A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
• Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease
• Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease
• Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease
• Development of Cognitive Assessment Tools in Parkinson Disease
• A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
• Augmenting Effects of L-DOPS With Carbidopa and Entacapone
• A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients
• Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
• Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
• Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study
• Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
• Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
• A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease
• Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk
• A Study of MK0657 in Parkinson's Disease Patients (0657-006)
• An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
• Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations
• An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease
• PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets
• Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
• REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study
• Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease
• Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients
• A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
• Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
• Low Dose Apomorphine and Parkinsonism
• Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients
• Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)
• Pivotal Study in Advanced Parkinsons Disease Patients
• Impact of Switching to Continuous Release Dopamine Agonists
• Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's Disease
• Study to Evaluate Initiation of Stalevo in Early Wearing-off
• Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease Patients
• A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects
• Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole
• Caffeine for Excessive Daytime Somnolence in Parkinson's Disease
• 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
• 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
• A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
• BIIB014 Phase 2a Monotherapy
• The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations
• NET-PD LS-1 Creatine in Parkinson's Disease
• Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
• Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease
• Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease
• Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
• Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)
• Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients
• A Study of E2007 In Patients With Parkinson's Disease
• Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion
• A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy
• An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
• SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
• Dyskinesia in Parkinson's Disease (Study P04501)
• Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
• A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
• Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
• A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
• Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease
• ALTROPANE® SPECT Imaging in Patients With Parkinson Disease
• Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease
• Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off
• A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease
• Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa
• Parkinson's Disease Evaluated by PET and the Effect of Memantine
• COMT Polymorphism and Entacapone Efficacy
• Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
• Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
• Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
• A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
• Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
• Methylphenidate and Parkinson's Disease
• Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
• Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease
• Profile of Depressive Symptoms in Parkinsons Disease
• Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
• An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
• SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
• Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
• An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
• A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's
• A Trial of MitoQ for the Treatment of People With Parkinson's Disease
• Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
• Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
• Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
• Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
• Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease
• Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease
• Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease
• Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
• Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease
• Ipratropium Spray for Drooling Saliva in Parkinson's Disease
• Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms
• Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia
• Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease
• Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease
• Treatment of Executive Dysfunction in Parkinson's Disease
• The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
• Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)
• Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease
• Pramipexole Conversion to Ropinirole Controlled Release (CR)
• Long-term Administration Study of SND 919 Tablets in Parkinson's Disease
• Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families
• Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit
• SLV308 for Treatment of Patients With Early Parkinson's Disease
• Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease
• A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease
• Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
• Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.
• Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa
• A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease
• A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease
• A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease
• Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease
• Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
• An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States
• POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease
• Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease
• Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.
• Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease
• Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease
• Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
• D-serine Adjuvant Treatment for Parkinson's Disease
• Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan
• Galantamine Executive Function in Parkinson's Disease
• 2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD
• Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
• Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
• Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
• Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease
• A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.
• Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa
• Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
• Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease
• Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months
• An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)
• A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
• A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
• An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
• An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
• A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
• Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease
• Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
• The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia
• A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations
• The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
• Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
• Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease
• A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With M
• A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)
• A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin
• A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.
• Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
• Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States
• Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease
• Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact
• A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease
• A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease
• A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
• Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression
• Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease
• Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome
• Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty
• Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease
• Stalevo in Early Wearing-Off Patients
• Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
• Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease
• Talampanel to Treat Parkinson's Disease
• Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
• Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
• Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy
• Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
• Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease
• Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
• Lisuride Patch to Treat Parkinson's Disease
• Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
• ACP-103 to Treat Parkinson's Disease
• Study of Antidepressants in Parkinson's Disease
• Levetiracetam Treatment of L-dopa Induced Dyskinesias
• NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485
• SAM-e for the Treatment of Depression in Patients With Parkinson's Disease
• Valerian to Improve Sleep in Patients With Parkinson's Disease
• National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial
• Treatment of Depression in Parkinson's Disease Trial
• Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease
• Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease
• Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
• Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
• Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
• JP-1730 to Treat Parkinson's Disease
• GM1 Ganglioside Effects on Parkinson's Disease
• Effects of Talampanel on Patients With Advanced Parkinson's Disease
• Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
• Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease
• The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease
• Donepezil to Treat Dementia in Parkinson's Disease
• Riluzole to Treat Parkinson's Disease
• EMD 128130 for the Treatment of Parkinson's Disease
• Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease
• KW-6002 to Treat Parkinson's Disease
• Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease
• Study of Clozapine for the Treatment of Psychosis in Patients With Idiopathic Parkinson's Disease
• Timing of Levodopa Treatment in Parkinson's Disease
• Parkinson's Disease Treatment With Coenzyme Q10
• Study of LY300164 for the Treatment of Parkinson's Disease
• Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients
• Treatment of Parkinson's Disease With a Transdermal Skin Patch
• Treatment of Parkinson's Disease With Eliprodil
• Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System